Could a drug combo replace stem cell transplants for some myeloma patients?

This phase 2 trial is testing whether a powerful four-drug combination can achieve such deep cancer remission that newly diagnosed multiple myeloma and amyloidosis patients can safely delay or avoid a stem cell transplant. Forty participants will receive six cycles of the drug combo, and those with minimal residual disease (very low cancer levels) will defer transplant. The study aims to see if this response-adapted strategy is feasible and effective.